RNAZ vs. ONVO, EGRX, CASI, AADI, NBRV, KRON, LEXX, CLNN, GANX, and OCUP
Should you be buying TransCode Therapeutics stock or one of its competitors? The main competitors of TransCode Therapeutics include Organovo (ONVO), Eagle Pharmaceuticals (EGRX), CASI Pharmaceuticals (CASI), Aadi Bioscience (AADI), Nabriva Therapeutics (NBRV), Kronos Bio (KRON), Lexaria Bioscience (LEXX), Clene (CLNN), Gain Therapeutics (GANX), and Ocuphire Pharma (OCUP). These companies are all part of the "medical" sector.
TransCode Therapeutics (NASDAQ:RNAZ) and Organovo (NASDAQ:ONVO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations.
TransCode Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 69.01%. Given TransCode Therapeutics' higher possible upside, analysts clearly believe TransCode Therapeutics is more favorable than Organovo.
Organovo received 188 more outperform votes than TransCode Therapeutics when rated by MarketBeat users. However, 88.89% of users gave TransCode Therapeutics an outperform vote while only 50.13% of users gave Organovo an outperform vote.
In the previous week, TransCode Therapeutics had 2 more articles in the media than Organovo. MarketBeat recorded 6 mentions for TransCode Therapeutics and 4 mentions for Organovo. Organovo's average media sentiment score of 0.97 beat TransCode Therapeutics' score of 0.18 indicating that Organovo is being referred to more favorably in the news media.
Organovo's return on equity of -182.88% beat TransCode Therapeutics' return on equity.
Organovo has higher revenue and earnings than TransCode Therapeutics. Organovo is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.
8.2% of Organovo shares are held by institutional investors. 1.5% of TransCode Therapeutics shares are held by company insiders. Comparatively, 4.0% of Organovo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
TransCode Therapeutics has a beta of -0.36, indicating that its share price is 136% less volatile than the S&P 500. Comparatively, Organovo has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
Summary
Organovo beats TransCode Therapeutics on 10 of the 15 factors compared between the two stocks.
Get TransCode Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for RNAZ and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TransCode Therapeutics Competitors List
Related Companies and Tools
